Presage Biosciences, a Seattle, WA-based oncology company advancing a drug development approach that incorporates human efficacy data much earlier in development and clinical trials, secured a strategic investment from Takeda Pharmaceutical Company Limited, through its venture capital arm, Takeda Ventures, Inc.
The terms of the transaction were not disclosed.
Led by Nathan Caffo, President, Presage incorporates is advancing its patented CIVO™ arrayed microinjection platform which allows for simultaneous assessment of multiple drugs or drug combinations directly in a single solid tumor while still in a patient’s body to assess efficacy, resistance and drug synergies in the tumor’s native microenvironment.
The company is now applying the technology across the development pipeline at Takeda, from identifying novel drug combinations to translating that work to the clinic. It is also validating the platform in the veterinary oncology setting in canine patients and expects to commence its second clinical study of the platform with the Seattle Cancer Care Alliance (SCCA) and the Fred Hutchinson Cancer Research Center in Q1 of 2016 in patients with soft tissue sarcomas.